News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
596,973 Results
Type
Article (60228)
Company Profile (103)
Press Release (536642)
Section
Business (170784)
Career Advice (2242)
Deals (25829)
Drug Delivery (80)
Drug Development (70913)
Employer Resources (148)
FDA (15599)
Job Trends (12900)
News (290907)
Policy (30200)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (4)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2912)
Academic (2)
Accelerated approval (2)
Adcomms (16)
Allergies (81)
Alliances (46466)
ALS (73)
Alzheimer's disease (1313)
Antibody-drug conjugate (ADC) (81)
Approvals (15593)
Artificial intelligence (214)
Autoimmune disease (11)
Automation (13)
Bankruptcy (226)
Best Places to Work (10197)
BIOSECURE Act (14)
Biosimilars (62)
Biotechnology (70)
Bladder cancer (42)
Brain cancer (23)
Breast cancer (215)
Cancer (1660)
Cardiovascular disease (120)
Career advice (1882)
Career pathing (25)
CAR-T (120)
Cell therapy (352)
Cervical cancer (16)
Clinical research (56369)
Collaboration (688)
Compensation (140)
Complete response letters (14)
COVID-19 (2546)
CRISPR (31)
C-suite (151)
Cystic fibrosis (89)
Data (1626)
Decentralized trials (2)
Denatured (25)
Depression (34)
Diabetes (198)
Diagnostics (5364)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (40)
Drug discovery (106)
Drug pricing (83)
Drug shortages (18)
Duchenne muscular dystrophy (62)
Earnings (68178)
Editorial (33)
Employer branding (20)
Employer resources (131)
Events (82123)
Executive appointments (511)
FDA (16593)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (554)
Gene editing (76)
Generative AI (24)
Gene therapy (247)
GLP-1 (610)
Government (4261)
Grass and pollen (4)
Guidances (42)
Healthcare (16236)
Huntington's disease (15)
IgA nephropathy (13)
Immunology and inflammation (66)
Indications (25)
Infectious disease (2652)
Inflammatory bowel disease (115)
Inflation Reduction Act (9)
Influenza (40)
Intellectual property (66)
Interviews (409)
IPO (11810)
IRA (42)
Job creations (3108)
Job search strategy (1595)
Kidney cancer (6)
Labor market (23)
Layoffs (371)
Leadership (13)
Legal (6281)
Liver cancer (59)
Lung cancer (235)
Lymphoma (112)
Machine learning (2)
Management (50)
Manufacturing (211)
MASH (51)
Medical device (10402)
Medtech (10406)
Mergers & acquisitions (14405)
Metabolic disorders (506)
Multiple sclerosis (55)
NASH (14)
Neurodegenerative disease (63)
Neuropsychiatric disorders (16)
Neuroscience (1705)
NextGen: Class of 2025 (5535)
Non-profit (4636)
Northern California (1805)
Now hiring (23)
Obesity (262)
Opinion (209)
Ovarian cancer (57)
Pain (63)
Pancreatic cancer (62)
Parkinson's disease (109)
Partnered (17)
Patents (153)
Patient recruitment (76)
Peanut (50)
People (46528)
Pharmaceutical (25)
Pharmacy benefit managers (10)
Phase I (17102)
Phase II (24111)
Phase III (19487)
Pipeline (785)
Podcasts (74)
Policy (101)
Postmarket research (2713)
Preclinical (8135)
Press Release (69)
Prostate cancer (86)
Psychedelics (29)
Radiopharmaceuticals (217)
Rare diseases (298)
Real estate (5065)
Recruiting (59)
Regulatory (21453)
Reports (32)
Research institute (2578)
Resumes & cover letters (354)
Rett syndrome (2)
RNA editing (2)
RSV (32)
Schizophrenia (58)
Series A (93)
Series B (52)
Service/supplier (11)
Sickle cell disease (42)
Southern California (1596)
Special edition (15)
Sponsored (28)
Startups (2861)
State (1)
Stomach cancer (9)
Supply chain (43)
The Weekly (48)
United States (16504)
Vaccines (635)
Venture capitalists (20)
Webinars (12)
Weight loss (172)
Women's health (25)
Worklife (13)
Date
Today (113)
Last 7 days (529)
Last 30 days (2562)
Last 365 days (28681)
2025 (5591)
2024 (29533)
2023 (33722)
2022 (44606)
2021 (48021)
2020 (46558)
2019 (40735)
2018 (30935)
2017 (28438)
2016 (28231)
2015 (32909)
2014 (26987)
2013 (24098)
2012 (24437)
2011 (24479)
2010 (23170)
Location
Africa (867)
Alabama (50)
Alaska (6)
Arizona (149)
Arkansas (10)
Asia (35527)
Australia (6414)
California (4137)
Canada (1503)
China (369)
Colorado (202)
Connecticut (220)
Delaware (95)
Europe (82513)
Florida (681)
Georgia (160)
Idaho (41)
Illinois (404)
India (21)
Indiana (236)
Iowa (6)
Japan (123)
Kansas (85)
Kentucky (18)
Louisiana (5)
Maine (35)
Maryland (703)
Massachusetts (3107)
Michigan (200)
Minnesota (250)
Mississippi (1)
Missouri (57)
Montana (18)
Nebraska (21)
Nevada (38)
New Hampshire (51)
New Jersey (1330)
New Mexico (29)
New York (1266)
North Carolina (816)
North Dakota (5)
Northern California (1805)
Ohio (151)
Oklahoma (12)
Oregon (24)
Pennsylvania (912)
Puerto Rico (6)
Rhode Island (22)
South America (1139)
South Carolina (15)
South Dakota (1)
Southern California (1596)
Tennessee (77)
Texas (612)
Utah (138)
Virginia (109)
Washington D.C. (50)
Washington State (435)
West Virginia (2)
Wisconsin (40)
596,973 Results for "food allergy research and education".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.
March 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Children’s Hospital of Philadelphia Researchers Lead First Study to Identify Molecular Basis of Food Allergy
February 5, 2025
·
4 min read
Press Releases
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
March 2, 2025
·
15 min read
Press Releases
EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management
October 31, 2024
·
2 min read
Press Releases
Food Allergy: LongBio’s LP-003 achieves its fourth IND approval
November 25, 2024
·
1 min read
Press Releases
Marius Pharmaceuticals Partners with Major Academic Medical Center on Education and Research Efforts for Oral Testosterone
March 4, 2025
·
9 min read
Pharm Country
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, announces data in a late-breaking poster presentation at this year’s American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting in Washington, D.C. supporting Oral Mucosal Immunotherapy as a potential new form of food allergy treatment.
February 22, 2024
·
5 min read
Drug Development
Roche’s Asthma Drug Xolair Shows Promise Against Food Allergies on Heels of FDA Approval
Approved earlier this month for children and adults with one or more food allergies, Xolair in a Phase III study reduced severe allergic reactions in patients suffering from multiple food allergies.
February 26, 2024
·
2 min read
·
Tristan Manalac
FDA
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
February 16, 2024
·
16 min read
FDA
FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
Novartis announced that the US Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
February 16, 2024
·
19 min read
1 of 59,698
Next